NASDAQ$PACB
Pacific Biosciences of California Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Pacific Biosciences' Q1 2022 earnings demonstrated strong revenue growth and strategic progress.
Pacific Biosciences reported a strong first quarter in 2022, marked by significant revenue growth driven by increased instrument sales. The company continues to focus on expanding its product portfolio and market reach.
- Revenue increased to $32.8 million, up 20% year-over-year.
- Instrument revenue grew significantly, reflecting strong customer demand.
- Continued progress in expanding the installed base of Sequel II/IIe systems.
- Strategic initiatives are underway to broaden the application of PacBio technology.
Headline financials
Revenue & EPS history
Pacific Biosciences · Revenue · Quarterly
$33.2M
Revenue by segment
Pacific Biosciences · $32.8M total across 3 segments · Q1 2022
- Instrument Revenue$17.4M+7.4%53.0%
- Service & Other Revenue$8.9M+242.3%27.1%
- Consumables Revenue$6.5M-34.3%19.8%
Forward guidance
PacBio anticipates continued growth and market expansion, driven by innovative product development and increasing adoption of its sequencing platforms. The company expects revenue growth and margin improvement throughout the year.
Tailwinds
- Expecting revenue between $130 million and $140 million for full year 2022.
- Continued expansion of the Sequel II/IIe installed base.
- Increased adoption of PacBio technology in key application areas.
- Advancements in product development to enhance sequencing capabilities.
- Strengthened commercial partnerships to expand market reach.
Headwinds
- Global supply chain constraints could impact instrument production and delivery.
- Increased competition in the long-read sequencing market.
- Uncertainties related to the COVID-19 pandemic may affect customer purchasing decisions.
- Fluctuations in foreign exchange rates could impact international revenue.
- Higher operating expenses due to increased R&D and commercial activities.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
+1.6%
Avg return
Earnings day
+2.4%
Avg return
5 days after
+4.1%
Avg return
30 days after
47%
29 / 62 earnings
Positive
+69.9%
Q3 2018
Best reaction
-27.2%
Q3 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -14.5% | -23.0% | -12.7% | |
| Q4 2025 | -7.1% | -11.4% | -27.7% | |
| Q3 2025 | -1.1% | -2.2% | +34.3% | |
| Q1 2025 | -8.4% | -8.3% | -5.0% | |
| Q4 2024 | +25.0% | +19.6% | -17.6% | |
| Q3 2024 | -13.2% | -16.6% | -23.4% | |
| Q2 2024 | +4.4% | -10.6% | -1.2% | |
| Q1 2024 | +5.4% | +32.7% | +19.6% | |
| Q4 2023 | +9.7% | -18.6% | -41.7% | |
| Q3 2023 | +20.9% | +15.2% | +48.7% | |
| Q2 2023 | -0.7% | -3.7% | -13.3% | |
| Q1 2023 | -2.8% | -0.5% | +13.6% | |
| Q4 2022 | +5.1% | -17.6% | -25.2% | |
| Q3 2022 | +2.1% | +11.8% | +31.9% | |
| Q2 2022 | +11.4% | +27.4% | -10.3% | |
| Q1 2022 | -4.5% | +2.9% | -7.1% | |
| Q4 2021 | +8.2% | +4.5% | -0.5% | |
| Q3 2021 | +6.6% | +5.3% | -22.1% | |
| Q2 2021 | +5.5% | +4.1% | +0.2% | |
| Q1 2021 | -0.2% | -3.4% | +4.7% | |
| Q4 2020 | +29.4% | +27.3% | -14.3% | |
| Q3 2020 | +16.1% | +18.2% | +62.7% | |
| Q2 2020 | -3.1% | +1.0% | +66.5% | |
| Q1 2020 | +9.4% | +11.6% | +26.7% | |
| Q4 2019 | -4.1% | -12.3% | -16.3% | |
| Q3 2019 | -2.8% | -4.8% | +3.5% | |
| Q2 2019 | +3.5% | +5.6% | +4.1% | |
| Q1 2019 | -0.3% | -1.3% | -9.6% | |
| Q4 2018 | -1.5% | -0.8% | +1.5% | |
| Q3 2018 | +69.9% | +71.2% | +75.7% | |
| Q2 2018 | +0.5% | +4.7% | +31.7% | |
| Q1 2018 | -8.7% | -6.9% | +0.8% | |
| Q4 2017 | -4.9% | -8.5% | -16.2% | |
| Q3 2017 | -27.2% | -33.9% | -27.2% | |
| Q2 2017 | +13.7% | +38.8% | +57.1% | |
| Q1 2017 | -19.4% | -20.3% | -27.2% | |
| Q4 2016 | -1.2% | -1.7% | +6.2% | |
| Q3 2016 | -20.4% | -12.7% | -17.4% | |
| Q2 2016 | +14.6% | +10.3% | +6.8% | |
| Q1 2016 | +18.2% | — | — | |
| Q4 2015 | -24.0% | — | — | |
| Q3 2015 | +9.7% | — | — | |
| Q2 2015 | -17.2% | — | — | |
| Q1 2015 | -0.5% | — | — | |
| Q4 2014 | -16.4% | — | — | |
| Q3 2014 | +11.8% | — | — | |
| Q2 2014 | +2.6% | — | — | |
| Q1 2014 | -5.6% | — | — | |
| Q4 2013 | +2.2% | — | — | |
| Q3 2013 | +0.0% | — | — | |
| Q2 2013 | +5.7% | — | — | |
| Q1 2013 | -0.4% | — | — | |
| Q4 2012 | +0.0% | — | — | |
| Q3 2012 | -5.4% | — | — | |
| Q2 2012 | +2.9% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | -12.7% | — | — | |
| Q3 2011 | -7.8% | — | — | |
| Q2 2011 | +8.9% | — | — | |
| Q1 2011 | -1.3% | — | — | |
| Q4 2010 | +2.7% | — | — | |
| Q3 2010 | +9.2% | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro